Skip to main contentSkip to search and navigation

UEF eREPOSITORY

    • English
    • suomi
  • English 
    • English
    • suomi
  • Login
View Item 
  •   Home
  • Artikkelit
  • Luonnontieteiden ja metsätieteiden tiedekunta
  • View Item
  •   Home
  • Artikkelit
  • Luonnontieteiden ja metsätieteiden tiedekunta
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases

Thumbnail
Files
Article (1.736Mb)
Self archived version
published version
Date
2018
Author(s)
O'Reilly, Meaghan A
Chinnery, Tricia
Yee, My-Linh
Wu, Sheng-Kai
Hynynen, Kullervo
Kerbel, Robert S
Czarnota, Gregory J
Pritchard, Kathleen I: Sahgal, Arjun
Unique identifier
10.1038/s41598-018-27335-y
Metadata
Show full item record
More information
Research Database SoleCris

Self-archived article

Citation
O'Reilly, Meaghan A. Chinnery, Tricia. Yee, My-Linh. Wu, Sheng-Kai. Hynynen, Kullervo. Kerbel, Robert S. Czarnota, Gregory J. Pritchard, Kathleen I: Sahgal, Arjun. (2018). Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases.  Scientific Reports, 8, 9013. 10.1038/s41598-018-27335-y.
Rights
© Authors
Licensed under
CC BY http://creativecommons.org/licenses/by/4.0/
Abstract

Leptomeningeal metastases (LM) are a serious complication of cancer in the central nervous system (CNS) and are diagnosed in approximately 5% of patients with solid tumors. Effective treatment using systemically administered therapeutics is hindered by the barriers of the CNS. Ultrasound can mediate delivery of drugs through these barriers. The goal of this study was to test the feasibility of using ultrasound-mediated drug delivery to improve the treatment of LM. LM was induced in the spinal cord of athymic rats by injecting HER2-expressing breast cancer cells into the subarachnoid space of the thoracic spine. Animals were divided into three groups: no treatment (n = 5), trastuzumab only (n = 6) or trastuzumab + focused ultrasound + microbubbles (FUS + MBs) (n = 7). Animals in groups 2 and 3 were treated weekly with intravenous trastuzumab +/− FUS + MBs for three weeks. Suppression in tumor growth was qualitatively observed by MRI in the group receiving ultrasound, and was confirmed by a significant difference in the tumor volume measured from the histology data (25 ± 17 mm3 vs 8 ± 5 mm3, p = 0.04 in the trastuzumab-only vs trastuzumab + FUS + MBs). This pilot study demonstrates the potential of ultrasound-mediated drug delivery as a novel treatment for LM. Future studies will extend this work to larger cohorts and the investigation of LM arising from other cancers.

URI
https://erepo.uef.fi/handle/123456789/7372
Link to the original item
http://dx.doi.org/10.1038/s41598-018-27335-y
Publisher
Springer Nature
Collections
  • Luonnontieteiden ja metsätieteiden tiedekunta [1109]
University of Eastern Finland
OpenAccess
eRepo
erepo@uef.fi
OpenUEF
Service provided by
the University of Eastern Finland Library
Library web pages
Twitter
Facebook
Youtube
Library blog
 sitemap
Search

Browse

All of the ArchiveResource types & CollectionsBy Issue DateAuthorsTitlesSubjectsFacultyDepartmentFull organizationSeriesMain subjectThis CollectionBy Issue DateAuthorsTitlesSubjectsFacultyDepartmentFull organizationSeriesMain subject

My Account

Login
University of Eastern Finland
OpenAccess
eRepo
erepo@uef.fi
OpenUEF
Service provided by
the University of Eastern Finland Library
Library web pages
Twitter
Facebook
Youtube
Library blog
 sitemap